Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Epilepsy
•
Internal Medicine
•
Neurology
•
Neuro-critical care
What is your threshold for initiating tocilizumab in patients with NORSE?
Related Questions
How do you decide on the treatment target of burst suppression pattern vs seizure cessation for patients with status epilepticus?
Is administration of IV or PO lacosamide, for management of status epilepticus, contraindicated in patient's with prolonged PR interval or first degree AV block on admission?
How do you approach use of newer anti-seizure medications for epilepsy patients on DOACs?
How would you manage a CVST secondary to a traumatic brain injury with the presence of intracranial hemorrhage?
How do you utilize at-home seizure monitoring devices for your patients with epilepsy?
How do you transition from Levetiracetam to Brivaracetam, particularly at doses of 1500 mg BID or higher?
In a patient with acute stroke/ICH/SDH/hyperammonemia at risk for rebound edema with new onset renal failure, do you prefer CRRT versus low and slow HD? How frequently do you monitor osmolarity?
How do you approach use of DMARDs and/or biologics for inflammatory arthritis in patients with a history of seizure disorder on anti-epileptic medications?
How do different inflammatory markers like CRP and ferritin contribute differently, if at all, to the monitoring of CART neurotoxicity?
Besides patient preference, what factors guide your decision to treat SeLECTs patients with antiseizure medications?
